Bank of New York Mellon’s Organogenesis Holdings ORGO Stock Holding History

Bank of New York Mellon’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$777K	Buy	319,643 +25,992	+9%	+$63.5K	﹤0.01%	3508
2026 Q1	$696K	Sell	293,651 -8,973	-3%	-$31.1K	﹤0.01%	3431
2025 Q4	$1.57M	Sell	302,624 -68,927	-19%	-$334K	﹤0.01%	2981
2025 Q3	$1.57M	Buy	371,551 +7,767	+2%	+$36.1K	﹤0.01%	2947
2025 Q2	$1.33M	Sell	363,784 -14,218	-4%	-$53K	﹤0.01%	2957
2025 Q1	$1.63M	Sell	378,002 -40,818	-10%	-$165K	﹤0.01%	2784
2024 Q4	$1.34M	Buy	418,820 +109,762	+36%	+$368K	﹤0.01%	2965
2024 Q3	$884K	Sell	309,058 -84,740	-22%	-$238K	﹤0.01%	3209
2024 Q2	$1.1M	Buy	393,798 +33,990	+9%	+$91.2K	﹤0.01%	3139
2024 Q1	$1.02M	Sell	359,808 -858	-0.2%	-$2.92K	﹤0.01%	3139
2023 Q4	$1.48M	Sell	360,666 -135,063	-27%	-$378K	﹤0.01%	2976
2023 Q3	$1.58M	Buy	495,729 +7,432	+2%	+$23.6K	﹤0.01%	2935
2023 Q2	$1.62M	Buy	488,297 +13,302	+3%	+$39.3K	﹤0.01%	2950
2023 Q1	$1.01M	Sell	474,995 -359,859	-43%	-$889K	﹤0.01%	3126
2022 Q4	$2.25M	Buy	834,854 +152,253	+22%	+$444K	﹤0.01%	2801
2022 Q3	$2.21M	Buy	682,601 +60,525	+10%	+$273K	﹤0.01%	2780
2022 Q2	$3.04M	Sell	622,076 -14,928	-2%	-$91.9K	﹤0.01%	2597
2022 Q1	$4.85M	Buy	637,004 +70,447	+12%	+$545K	﹤0.01%	2449
2021 Q4	$5.23M	Buy	566,557 +58,222	+11%	+$618K	﹤0.01%	2447
2021 Q3	$7.24M	Buy	508,335 +92,690	+22%	+$1.44M	﹤0.01%	2304
2021 Q2	$6.91M	Buy	415,645 +263,566	+173%	+$4.91M	﹤0.01%	2338
2021 Q1	$2.77M	Buy	152,079 +55,049	+57%	+$746K	﹤0.01%	2739
2020 Q4	$731K	Buy	97,030 +41,125	+74%	+$195K	﹤0.01%	3431
2020 Q3	$215K	Buy	55,905 +567	+1%	+$2.24K	﹤0.01%	3823
2020 Q2	$213K	Buy	55,338 +26,963	+95%	+$97.2K	﹤0.01%	3782
2020 Q1	$91K	Buy	28,375 +2,135	+8%	+$9.14K	﹤0.01%	3874
2019 Q4	$126K	Hold	26,240	–	–	﹤0.01%	3992
2019 Q3	$173K	Sell	26,240 -1,305	-5%	-$7.26K	﹤0.01%	3928
2019 Q2	$210K	Buy	+27,545	New	+$203K	﹤0.01%	3908

Other funds holding ORGO

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon's ORGO Position: Q2 2026 in Review

Bank of New York Mellon increased its Organogenesis Holdings (ORGO) stake by 8.9% in Q2 2026, buying an estimated $63.5K and bringing the position to 319,643 shares worth $777K. The position accounts for ﹤0.01% of the portfolio, ranked #3508.

Bank of New York Mellon first reported a position in ORGO in Q2 2019 and has held it in 29 quarters since. The position peaked at $7.24M in Q3 2021. 134 funds tracked by Wall St. Rank hold ORGO as of Q2 2026.

Bank of New York Mellon held 319,643 shares of Organogenesis Holdings worth $777K as of Q2 2026.
Bank of New York Mellon bought 25,992 Organogenesis Holdings shares in Q2 2026, an estimated $63.5K.
Organogenesis Holdings made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3508 holding.
Bank of New York Mellon first reported a position in Organogenesis Holdings in Q2 2019 and has held it in 29 quarters since.
Bank of New York Mellon's Organogenesis Holdings position peaked at $7.24M in Q3 2021.
134 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.